secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2026-09-21T20:05:54+00:00
Accession:  0001140361-26-037234
Event type: other
Sentiment:  neutral
Materiality: 0.05
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech updates corporate presentation deck; no new trial or financial data disclosed
--------------------------------------------------------------------------------

- On September 21, 2026, PDS Biotechnology (NASDAQ: PDSB) posted an updated corporate presentation.
- Deck titled 'Overview of PDS Biotech Drug Development Programs (Oncology)' — oncology immunotherapy focus.
- Exhibit text provided contains only the cover slide; no dosing, efficacy, or financial figures included.
- Filing signed by Frank Bedu-Addo, Ph.D., President and CEO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/0001140361-26-037234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036126037234/ef20082538_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-037234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer